Related Experiment Videos
Pre-clinical toxicity of IL-4: a model for studying protein therapeutics
J H Dean1, J B Cornacoff, T A Barbolt
1Sterling Winthrop Pharmaceuticals Research Division, Sterling Winthrop Inc., Rensselaer, NY 12144.
Abstract:
The purpose of this presentation was to review issues and findings in the pre-clinical development and evaluation of recombinant human protein therapeutics. Since human cytokines and lymphokines are endogenous proteins, their pre-clinical development and evaluation would seem straightforward and their toxicities minimal. Unfortunately, the pre-clinical development of this class of agents has been problematic and confounding. Some of the clinical toxicities and pharmacodynamics have been predicted by the pre-clinical evaluation and others have not. Some molecules are species specific which limits species selection for pre-clinical evaluation. Other confounding issues include: route of exposure, synergy of toxicity with other lymphokines, length of study design, immunogenicity, predictiveness of pre-clinical evaluation and iatrogenic toxicities. An approach used by SWPRD in the evaluation of this class of molecules was discussed. Insight gained during the pre-clinical and clinical development of these molecules should simplify the further development of protein therapeutics that follow. Specific studies with recombinant human interleukin-4 (rhuIL-4) were reviewed in detail as part of a pre-clinical safety evaluation. Native IL-4 has properties that exemplify many of the immune recognition-induced lymphokines and is produced principally by activated T-lymphocytes CD4+. It is a co-factor in B-cell proliferation and enhances ex vivo B-cell expansion and is believed to be a candidate for the treatment of refractory cancer based on this immune enhancement ability. rhuIL-4 is a 15,400 molecular weight cytokine produced in a yeast expression system.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Pre-clinical evaluation of recombinant protein therapeutics, like recombinant human interleukin-4 (rhuIL-4), presents challenges. Despite initial assumptions, predicting clinical toxicities and pharmacodynamics requires careful study design and consideration of various confounding factors.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Recombinant human protein therapeutics, including cytokines and lymphokines, are endogenous proteins.
- Their pre-clinical development is often complex, with some toxicities and pharmacodynamics not predicted by initial evaluations.
Purpose of the Study:
- To review challenges and findings in the pre-clinical development and evaluation of recombinant human protein therapeutics.
- To detail specific studies of recombinant human interleukin-4 (rhuIL-4) as part of a pre-clinical safety evaluation.
Main Methods:
- Review of pre-clinical development issues for cytokines and lymphokines.
- Detailed examination of specific studies involving recombinant human interleukin-4 (rhuIL-4).
- Discussion of an approach used by SWPRD for evaluating these molecules.
Main Results:
- Pre-clinical evaluation has limitations in predicting clinical toxicities and pharmacodynamics for protein therapeutics.
- Species specificity, route of exposure, immunogenicity, and study design length are confounding factors.
- Recombinant human interleukin-4 (rhuIL-4) exhibits immune-enhancing properties, making it a potential candidate for refractory cancer treatment.
Conclusions:
- The pre-clinical development of recombinant protein therapeutics is complex and requires careful consideration of numerous factors.
- Insights gained from developing molecules like rhuIL-4 can simplify future protein therapeutic development.
- Further research is needed to improve the predictiveness of pre-clinical evaluations for protein therapeutics.